VANCOUVER, British Columbia, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that its division, C3 Global Biosciences (C3GBS) has agreed in principle to acquire the rights to become the exclusive worldwide distributor of Advanced Brain Monitoring’s (ABM) Electroencephalogram (EEG) technology in the phytoceutical field, specifically the cannabis community.
For the last 15 years, ABM has challenged conventional thinking by developing innovative medical devices that provide superior patient experience, lower healthcare costs, and improved quality of care. With this versatile, state of the art wireless EEG system, interpretation of physiological signals across a wide variety of real-world applications are finally here. The EEG system will allow physicians and researchers real-time feedback on the effect of Cannabis products. The EEG device is reimbursable and has designated CPT codes for physicians to submit to health insurance companies.
Andrew Serafini, C3GBS President, says, “The need to fast-track and bring to market therapeutic novel compounds that possess great potential in human diseases have a need for an FDA-approved drug validation technology that should become mandatory. The cannabis industry lacks verification methodologies and C3GBS is excited to bring the EEG technology to the forefront to help further discover the benefits in real time. This will invariably result in evidence-based data gathering to help support and guide the healthcare practitioner.”
“This is another monumental step taken by Isodiol and C3GBS to be the global leader in cannabis research, science, innovation, and technology to positively impact patient outcomes. The EEG system offers another diagnostic tool, that is FDA approved, to help understand how cannabis is beneficial to the human body,” added Isodiol CEO, Marcos Agramont.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia, and Europe.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.